NCT02205047 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02205047
Title	Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION)
Acronym	INNOVATION
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	European Organisation for Research and Treatment of Cancer - EORTC
Indications	gastroesophageal junction adenocarcinoma gastric adenocarcinoma
Therapies	Capecitabine + Cisplatin Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Capecitabine + Cisplatin + Pertuzumab + Trastuzumab
Age Groups:	senior \| adult
Covered Countries	NOR \| NLD \| ITA \| GBR \| FRA \| EST \| ESP \| DEU \| CHE \| BEL

No variant requirements are available.